Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.

Read MORE

TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ — Therapix Biosciences Ltd. (“Therapix” or the “Company”) (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with…

Share:

Author: HEDGE

Executive Editor and Founder of HEDGEaccordingly.com. Hedge Was Founded in January 22, 2008. Learn more about HEDGEaccordingly